BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30

• Drug Development

  APHINITY Study Shows Genentech’s Perjeta-Based Regimen Reduced The Risk Of Invasive Cancer Returning Compared To Herceptin And Chemotherapy In HER2-Positive Early Breast Cancer

  June 5, 2017

   · 

  1 min read
• Drug Development

  ARMO BioSciences Announces Encouraging Survival Data Observed In Patients With Advanced Pancreatic Cancer In Phase I/Ib Trial Of Immunotherapy AM0010

  June 5, 2017

   · 

  6 min read
• Drug Development

  Amgen Presents New Phase II Data On IMLYGIC (Talimogene Laherparepvec) Investigational Combination At ASCO 2017

  June 5, 2017

   · 

  16 min read
• Business

  Thermo Fisher Scientific And Biognosys Announce Co-Marketing Agreement To Create Industry-Leading Data-Independent Acquisition Workflows

  June 5, 2017

   · 

  3 min read
• Drug Development

  Incyte Release: Clinical Trial Data For Combination Of Epacadostat And Opdivo (Nivolumab) Demonstrate Durable Clinical Responses In Patients With Melanoma And Head And Neck Cancer

  June 5, 2017

   · 

  1 min read
• Drug Development

  Bristol-Myers Squibb Release: Encouraging Disease Control Rates Observed With Nivolumab Alone Or In Combination With Ipilimumab In Refractory Or Relapsing Malignant Pleural Mesothelioma Patients: Results From IFCT-1501 MAPS-2 Trial

  June 5, 2017

   · 

  1 min read
• Drug Development

  Boehringer Ingelheim Release: Encouraging Phase II Survival Data For Oral Nintedanib In Malignant Pleural Mesothelioma Presented At ASCO 2017

  June 5, 2017

   · 

  5 min read
• Drug Development

  Sierra Oncology Reports Encouraging Initial Progress From Ongoing Phase I Clinical Trials Of Chk1 Inhibitor SRA737

  June 5, 2017

   · 

  10 min read
• Drug Development

  Forge Therapeutics And Evotec AG Present First Efficacy Data For LpxC Inhibitor In UTI Model At ASM Microbe 2017

  June 5, 2017

   · 

  3 min read
• Drug Development

  Phase III Study Showed Genentech’s Alecensa (Alectinib) Reduced The Risk Of Disease Progression Or Death By More Than Half Versus Crizotinib As First-Line Treatment In A Specific Type Of Lung Cancer

  June 5, 2017

   · 

  10 min read